<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01807117</url>
  </required_header>
  <id_info>
    <org_study_id>CASE8212</org_study_id>
    <secondary_id>NCI-2013-00511</secondary_id>
    <nct_id>NCT01807117</nct_id>
  </id_info>
  <brief_title>PET-MRI in Diagnosing Patients With Colon or Rectal Cancer</brief_title>
  <official_title>Evaluation of PET-MRI in Initial Staging of High Grade Rectal Cancer Patients and in the Follow up of Colorectal Cancer Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies positron emission tomography (PET)-magnetic resonance&#xD;
      imaging (MRI) and PET-computed tomography (CT) as diagnostic imaging in patients with colon&#xD;
      and/or rectal cancer. New diagnostic imaging procedures, such as PET-MRI, may help find and&#xD;
      diagnose rectal cancer or recurrence of colorectal cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To test the diagnostic performance of PET- MRI in the staging of preoperative high-grade&#xD;
      rectal cancer patients, defined by T3 stage or higher or N1 stage or higher or presence of&#xD;
      metastasis, that are referred to PET-CT and MRI.&#xD;
&#xD;
      II. To test the diagnostic performance of PET-MRI the follow up of colorectal cancer patients&#xD;
      that are referred to PET-CT with or without a diagnostic MRI request by their physicians.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To test different attenuation correction MR sequences and novel diagnostic MR sequences.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2013</start_date>
  <completion_date type="Actual">March 5, 2014</completion_date>
  <primary_completion_date type="Actual">March 5, 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Standardized Uptake Value (SUVmax) in Physiologic Regions and Fluorodeoxyglucose (FDG) Avid Lesions in Participants Where PET-CT Was Performed Prior to the PET-MRI</measure>
    <time_frame>Up to 6 months (each scan taking an average of 45 minutes)</time_frame>
    <description>SUV max in physiologic regions (blood pool, liver) and FDG avid lesions, in which the PET-CT was performed prior to the PET-MRI. SUVmax is defined as [tissue concentration (MBq/g) x body weight (g)]/[injected dose (MBq/g)]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Standardized Uptake Value (SUVmax) in Physiologic Regions and FDG Avid Lesions in Participants Where PET-MRI Was Performed Prior to the PET-CT</measure>
    <time_frame>Up to 6 months (each scan taking an average of 45 minutes)</time_frame>
    <description>SUV max in physiologic regions (blood pool, liver) and FDG avid lesions, in which the PET-MRI was performed prior to the PET-CT. SUVmax is defined as [tissue concentration (MBq/g) x body weight (g)]/[injected dose (MBq/g)]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SUVmax in Which the PET-CT Was Performed Prior to the PET-MRI.</measure>
    <time_frame>Up to 6 months (each scan taking an average of 45 minutes)</time_frame>
    <description>SUVmax in FDG avid lesions in which the PET/CT was performed prior to the PET-MRI.&#xD;
SUVmax is defined as [tissue concentration (MBq/g) x body weight (g)]/[injected dose (MBq/g)]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SUVmax in Which the PET-MRI Was Performed Prior to the PET-CT</measure>
    <time_frame>Up to 6 months (each scan taking an average of 45 minutes)</time_frame>
    <description>SUVmax in FDG avid lesions in which the PET-MRI was performed prior to the PET-CT SUVmax is defined as [tissue concentration (MBq/g) x body weight (g)]/[injected dose (MBq/g)]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SUVmax Ratio in Which the PET-CT Was Performed Prior to the PET-MRI</measure>
    <time_frame>Up to 6 months (each scan taking an average of 45 minutes)</time_frame>
    <description>SUVmax ratio in FDG avid lesions in which the PET-CT was performed prior to the PET-MRI&#xD;
SUVmax is defined as [tissue concentration (MBq/g) x body weight (g)]/[injected dose (MBq/g)]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SUVmax Ratio in Which the PET-MRI Was Performed Prior to the PET-CT</measure>
    <time_frame>Up to 6 months (each scan taking an average of 45 minutes)</time_frame>
    <description>SUVmax ratio in FDG avid lesions in which the PET-MRI was performed prior to the PET-CT SUVmax is defined as [tissue concentration (MBq/g) x body weight (g)]/[injected dose (MBq/g)]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>True Positive Rate</measure>
    <time_frame>Up to 6 months (each scan taking an average of 45 minutes)</time_frame>
    <description>True positive rate for both modalities - TP/TP+FN&#xD;
TP = true positives FN = False negatives</description>
  </primary_outcome>
  <primary_outcome>
    <measure>True Negative Rate</measure>
    <time_frame>Up to 6 months (each scan taking an average of 45 minutes)</time_frame>
    <description>True negative rate for both modalities - TN/TN+FP&#xD;
TN = true negatives FP = False positives</description>
  </primary_outcome>
  <primary_outcome>
    <measure>False Negative Rate</measure>
    <time_frame>Up to 6 months (each scan taking an average of 45 minutes)</time_frame>
    <description>False negative rate for both modalities - FN/FN+TP&#xD;
FN = False negatives TP = true positives</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Lesions Identified by PET-CT That Were Correctly Detected by PET-MRI</measure>
    <time_frame>Up to 6 months (each scan taking an average of 45 minutes)</time_frame>
    <description>On a per-lesion basis, proportion of lesions identified by PET-CT that were correctly detected by PET-MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive Predictive Values for PET-CT and PET-MRI</measure>
    <time_frame>Up to 6 months (each scan taking an average of 45 minutes)</time_frame>
    <description>Percent of true positive rate of diagnostic accuracy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Negative Predictive Values for PET-CT and PET-MRI</measure>
    <time_frame>Up to 6 months (each scan taking an average of 45 minutes)</time_frame>
    <description>Percent of true negative rate of diagnostic accuracy</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Recurrent Colon Cancer</condition>
  <condition>Recurrent Rectal Cancer</condition>
  <condition>Stage IIA Colon Cancer</condition>
  <condition>Stage IIA Rectal Cancer</condition>
  <condition>Stage IIB Colon Cancer</condition>
  <condition>Stage IIB Rectal Cancer</condition>
  <condition>Stage IIC Colon Cancer</condition>
  <condition>Stage IIC Rectal Cancer</condition>
  <condition>Stage IIIA Colon Cancer</condition>
  <condition>Stage IIIA Rectal Cancer</condition>
  <condition>Stage IIIB Colon Cancer</condition>
  <condition>Stage IIIB Rectal Cancer</condition>
  <condition>Stage IIIC Colon Cancer</condition>
  <condition>Stage IIIC Rectal Cancer</condition>
  <condition>Stage IVA Colon Cancer</condition>
  <condition>Stage IVA Rectal Cancer</condition>
  <condition>Stage IVB Colon Cancer</condition>
  <condition>Stage IVB Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Diagnostic (PET-CT and PET-MRI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>positron emission tomography</intervention_name>
    <description>Undergo fludeoxyglucose F 18 PET-CT and PET-MRI</description>
    <arm_group_label>Diagnostic (PET-CT and PET-MRI)</arm_group_label>
    <other_name>FDG-PET</other_name>
    <other_name>PET</other_name>
    <other_name>PET scan</other_name>
    <other_name>tomography, emission computed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>computed tomography</intervention_name>
    <description>Undergo fludeoxyglucose F 18 PET-CT and PET-MRI</description>
    <arm_group_label>Diagnostic (PET-CT and PET-MRI)</arm_group_label>
    <other_name>tomography, computed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>magnetic resonance imaging</intervention_name>
    <description>Undergo fludeoxyglucose F 18 PET-CT and PET-MRI</description>
    <arm_group_label>Diagnostic (PET-CT and PET-MRI)</arm_group_label>
    <other_name>MRI</other_name>
    <other_name>NMR imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>nuclear magnetic resonance imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>fludeoxyglucose F 18</intervention_name>
    <description>Undergo fludeoxyglucose F 18 PET-CT and PET-MRI</description>
    <arm_group_label>Diagnostic (PET-CT and PET-MRI)</arm_group_label>
    <other_name>18FDG</other_name>
    <other_name>FDG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Either having a T3 (the cancer has grown through the muscularis propria and into the&#xD;
             outermost layers of the colon or rectum but not through them) or higher, node&#xD;
             positivity or metastatic lesion in the context of rectal cancer or being studied for&#xD;
             colorectal cancer follow up, independent of the renal function&#xD;
&#xD;
          -  PET-CT should be requested by a referring physician; in the case of having an MR&#xD;
             requested as well, it will be reported from the MRI images generated in the PET-MRI&#xD;
&#xD;
          -  Stable physical medical conditions to undergo a MRI&#xD;
&#xD;
          -  Informed consent must be given and signed prior to study enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refuse to give and/or sign the informed consent&#xD;
&#xD;
          -  Subjects who do not meet the above mentioned inclusion criteria&#xD;
&#xD;
          -  Subjects who have a pacemaker&#xD;
&#xD;
          -  Subjects who have a metallic prostheses either in the pelvis or in the abdomen that&#xD;
             will interfere with the MR imaging of that anatomical area&#xD;
&#xD;
          -  Subjects who suffer from claustrophobia&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Cognitive impairment that affects the subject's ability to give consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raj Paspulati, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 6, 2013</study_first_submitted>
  <study_first_submitted_qc>March 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2013</study_first_posted>
  <results_first_submitted>February 23, 2021</results_first_submitted>
  <results_first_submitted_qc>April 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 18, 2021</results_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 18, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT01807117/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT01807117/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Diagnostic (PET-CT and PET-MRI)</title>
          <description>Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.&#xD;
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease diagnosis not a study disease</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants who were put on study</population>
      <group_list>
        <group group_id="B1">
          <title>Diagnostic (PET-CT and PET-MRI)</title>
          <description>Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.&#xD;
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>years</title>
              <category_list>
                <category>
                  <title>20-29</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>30-39</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>40-49</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>50-59</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>60-69</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>70-79</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>80-89</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Standardized Uptake Value (SUVmax) in Physiologic Regions and Fluorodeoxyglucose (FDG) Avid Lesions in Participants Where PET-CT Was Performed Prior to the PET-MRI</title>
        <description>SUV max in physiologic regions (blood pool, liver) and FDG avid lesions, in which the PET-CT was performed prior to the PET-MRI. SUVmax is defined as [tissue concentration (MBq/g) x body weight (g)]/[injected dose (MBq/g)]</description>
        <time_frame>Up to 6 months (each scan taking an average of 45 minutes)</time_frame>
        <population>Participants who received PET-CT as initial imaging followed by PET-MRI. Evaluable lesions for this group.</population>
        <group_list>
          <group group_id="O1">
            <title>Blood Pool</title>
            <description>Physiologic region - Diagnostic (PET-CT and PET-MRI) arm&#xD;
Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.&#xD;
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI</description>
          </group>
          <group group_id="O2">
            <title>Liver</title>
            <description>Physiologic region - Diagnostic (PET-CT and PET-MRI) arm Physiologic region - Diagnostic (PET-CT and PET-MRI) arm&#xD;
Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.&#xD;
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Standardized Uptake Value (SUVmax) in Physiologic Regions and Fluorodeoxyglucose (FDG) Avid Lesions in Participants Where PET-CT Was Performed Prior to the PET-MRI</title>
          <description>SUV max in physiologic regions (blood pool, liver) and FDG avid lesions, in which the PET-CT was performed prior to the PET-MRI. SUVmax is defined as [tissue concentration (MBq/g) x body weight (g)]/[injected dose (MBq/g)]</description>
          <population>Participants who received PET-CT as initial imaging followed by PET-MRI. Evaluable lesions for this group.</population>
          <units>SUV max</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PET-CT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="1.2" upper_limit="2.5"/>
                    <measurement group_id="O2" value="2.3" lower_limit="1.7" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET-MRI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.8" upper_limit="1.6"/>
                    <measurement group_id="O2" value="2.1" lower_limit="1.6" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Standardized Uptake Value (SUVmax) in Physiologic Regions and FDG Avid Lesions in Participants Where PET-MRI Was Performed Prior to the PET-CT</title>
        <description>SUV max in physiologic regions (blood pool, liver) and FDG avid lesions, in which the PET-MRI was performed prior to the PET-CT. SUVmax is defined as [tissue concentration (MBq/g) x body weight (g)]/[injected dose (MBq/g)]</description>
        <time_frame>Up to 6 months (each scan taking an average of 45 minutes)</time_frame>
        <population>Participants who received PET-MRI was performed prior to the PET-CT. Evaluable lesions for this group.</population>
        <group_list>
          <group group_id="O1">
            <title>Blood Pool</title>
            <description>Physiologic region - Diagnostic (PET-CT and PET-MRI) arm&#xD;
Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.&#xD;
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI</description>
          </group>
          <group group_id="O2">
            <title>Liver</title>
            <description>Physiologic region - Diagnostic (PET-CT and PET-MRI) arm Physiologic region - Diagnostic (PET-CT and PET-MRI) arm&#xD;
Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.&#xD;
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Standardized Uptake Value (SUVmax) in Physiologic Regions and FDG Avid Lesions in Participants Where PET-MRI Was Performed Prior to the PET-CT</title>
          <description>SUV max in physiologic regions (blood pool, liver) and FDG avid lesions, in which the PET-MRI was performed prior to the PET-CT. SUVmax is defined as [tissue concentration (MBq/g) x body weight (g)]/[injected dose (MBq/g)]</description>
          <population>Participants who received PET-MRI was performed prior to the PET-CT. Evaluable lesions for this group.</population>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PET-CT</title>
            </class>
            <class>
              <title>PET-MRI</title>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>SUVmax in Which the PET-CT Was Performed Prior to the PET-MRI.</title>
        <description>SUVmax in FDG avid lesions in which the PET/CT was performed prior to the PET-MRI.&#xD;
SUVmax is defined as [tissue concentration (MBq/g) x body weight (g)]/[injected dose (MBq/g)]</description>
        <time_frame>Up to 6 months (each scan taking an average of 45 minutes)</time_frame>
        <population>Participants who received PET-CT as initial imaging followed by PET-MRI. Evaluable lesions for this group.</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (PET-CT and PET-MRI)</title>
            <description>Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.&#xD;
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI</description>
          </group>
        </group_list>
        <measure>
          <title>SUVmax in Which the PET-CT Was Performed Prior to the PET-MRI.</title>
          <description>SUVmax in FDG avid lesions in which the PET/CT was performed prior to the PET-MRI.&#xD;
SUVmax is defined as [tissue concentration (MBq/g) x body weight (g)]/[injected dose (MBq/g)]</description>
          <population>Participants who received PET-CT as initial imaging followed by PET-MRI. Evaluable lesions for this group.</population>
          <units>SUV max</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PET-CT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="0.5" upper_limit="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET-MRI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="1.6" upper_limit="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>SUVmax in Which the PET-MRI Was Performed Prior to the PET-CT</title>
        <description>SUVmax in FDG avid lesions in which the PET-MRI was performed prior to the PET-CT SUVmax is defined as [tissue concentration (MBq/g) x body weight (g)]/[injected dose (MBq/g)]</description>
        <time_frame>Up to 6 months (each scan taking an average of 45 minutes)</time_frame>
        <population>Participants who received PET-MRI as initial imaging followed by PET-CT. Evaluable lesions for this group.</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (PET-CT and PET-MRI)</title>
            <description>Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.&#xD;
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI</description>
          </group>
        </group_list>
        <measure>
          <title>SUVmax in Which the PET-MRI Was Performed Prior to the PET-CT</title>
          <description>SUVmax in FDG avid lesions in which the PET-MRI was performed prior to the PET-CT SUVmax is defined as [tissue concentration (MBq/g) x body weight (g)]/[injected dose (MBq/g)]</description>
          <population>Participants who received PET-MRI as initial imaging followed by PET-CT. Evaluable lesions for this group.</population>
          <units>SUV max</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PET-CT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" lower_limit="3.4" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET-MRI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="2.3" upper_limit="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>SUVmax Ratio in Which the PET-CT Was Performed Prior to the PET-MRI</title>
        <description>SUVmax ratio in FDG avid lesions in which the PET-CT was performed prior to the PET-MRI&#xD;
SUVmax is defined as [tissue concentration (MBq/g) x body weight (g)]/[injected dose (MBq/g)]</description>
        <time_frame>Up to 6 months (each scan taking an average of 45 minutes)</time_frame>
        <population>Participants who received PET-CT as initial imaging followed by PET-MRI. Evaluable lesions for this group.</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (PET-CT and PET-MRI)</title>
            <description>Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.&#xD;
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI</description>
          </group>
        </group_list>
        <measure>
          <title>SUVmax Ratio in Which the PET-CT Was Performed Prior to the PET-MRI</title>
          <description>SUVmax ratio in FDG avid lesions in which the PET-CT was performed prior to the PET-MRI&#xD;
SUVmax is defined as [tissue concentration (MBq/g) x body weight (g)]/[injected dose (MBq/g)]</description>
          <population>Participants who received PET-CT as initial imaging followed by PET-MRI. Evaluable lesions for this group.</population>
          <units>SUV max ratio</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PET-CT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0.2" upper_limit="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET-MRI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="0.8" upper_limit="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>SUVmax Ratio in Which the PET-MRI Was Performed Prior to the PET-CT</title>
        <description>SUVmax ratio in FDG avid lesions in which the PET-MRI was performed prior to the PET-CT SUVmax is defined as [tissue concentration (MBq/g) x body weight (g)]/[injected dose (MBq/g)]</description>
        <time_frame>Up to 6 months (each scan taking an average of 45 minutes)</time_frame>
        <population>Participants who received PET-MRI as initial imaging followed by PET-CT. Evaluable lesions for this group.</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (PET-CT and PET-MRI)</title>
            <description>Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.&#xD;
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI</description>
          </group>
        </group_list>
        <measure>
          <title>SUVmax Ratio in Which the PET-MRI Was Performed Prior to the PET-CT</title>
          <description>SUVmax ratio in FDG avid lesions in which the PET-MRI was performed prior to the PET-CT SUVmax is defined as [tissue concentration (MBq/g) x body weight (g)]/[injected dose (MBq/g)]</description>
          <population>Participants who received PET-MRI as initial imaging followed by PET-CT. Evaluable lesions for this group.</population>
          <units>SUV max</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PET-CT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="1.5" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET-MRI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.2" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>True Positive Rate</title>
        <description>True positive rate for both modalities - TP/TP+FN&#xD;
TP = true positives FN = False negatives</description>
        <time_frame>Up to 6 months (each scan taking an average of 45 minutes)</time_frame>
        <population>Evaluable lesions for this group.</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (PET-CT and PET-MRI)</title>
            <description>Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.&#xD;
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI</description>
          </group>
        </group_list>
        <measure>
          <title>True Positive Rate</title>
          <description>True positive rate for both modalities - TP/TP+FN&#xD;
TP = true positives FN = False negatives</description>
          <population>Evaluable lesions for this group.</population>
          <units>percentage of true positive results</units>
          <param>Number</param>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PET-CT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET-MRI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>True Negative Rate</title>
        <description>True negative rate for both modalities - TN/TN+FP&#xD;
TN = true negatives FP = False positives</description>
        <time_frame>Up to 6 months (each scan taking an average of 45 minutes)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (PET-CT and PET-MRI)</title>
            <description>Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.&#xD;
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI</description>
          </group>
        </group_list>
        <measure>
          <title>True Negative Rate</title>
          <description>True negative rate for both modalities - TN/TN+FP&#xD;
TN = true negatives FP = False positives</description>
          <units>percent</units>
          <param>Number</param>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PET-CT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET-MRI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>False Negative Rate</title>
        <description>False negative rate for both modalities - FN/FN+TP&#xD;
FN = False negatives TP = true positives</description>
        <time_frame>Up to 6 months (each scan taking an average of 45 minutes)</time_frame>
        <population>Evaluable lesions for this group.</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (PET-CT and PET-MRI)</title>
            <description>Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.&#xD;
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI</description>
          </group>
        </group_list>
        <measure>
          <title>False Negative Rate</title>
          <description>False negative rate for both modalities - FN/FN+TP&#xD;
FN = False negatives TP = true positives</description>
          <population>Evaluable lesions for this group.</population>
          <units>percent</units>
          <param>Number</param>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PET-CT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET-MRI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Lesions Identified by PET-CT That Were Correctly Detected by PET-MRI</title>
        <description>On a per-lesion basis, proportion of lesions identified by PET-CT that were correctly detected by PET-MRI</description>
        <time_frame>Up to 6 months (each scan taking an average of 45 minutes)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (PET-CT and PET-MRI)</title>
            <description>Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.&#xD;
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Lesions Identified by PET-CT That Were Correctly Detected by PET-MRI</title>
          <description>On a per-lesion basis, proportion of lesions identified by PET-CT that were correctly detected by PET-MRI</description>
          <units>Lesions</units>
          <param>Number</param>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Positive Predictive Values for PET-CT and PET-MRI</title>
        <description>Percent of true positive rate of diagnostic accuracy.</description>
        <time_frame>Up to 6 months (each scan taking an average of 45 minutes)</time_frame>
        <population>Evaluable lesions for this group.</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (PET-CT and PET-MRI)</title>
            <description>Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.&#xD;
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI</description>
          </group>
        </group_list>
        <measure>
          <title>Positive Predictive Values for PET-CT and PET-MRI</title>
          <description>Percent of true positive rate of diagnostic accuracy.</description>
          <population>Evaluable lesions for this group.</population>
          <units>Percent of true positives</units>
          <param>Number</param>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PET-CT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET-MRI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Negative Predictive Values for PET-CT and PET-MRI</title>
        <description>Percent of true negative rate of diagnostic accuracy</description>
        <time_frame>Up to 6 months (each scan taking an average of 45 minutes)</time_frame>
        <population>Evaluable lesions for this group.</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (PET-CT and PET-MRI)</title>
            <description>Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.&#xD;
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI</description>
          </group>
        </group_list>
        <measure>
          <title>Negative Predictive Values for PET-CT and PET-MRI</title>
          <description>Percent of true negative rate of diagnostic accuracy</description>
          <population>Evaluable lesions for this group.</population>
          <units>Percent of true negatives</units>
          <param>Number</param>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PET-CT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PET-MRI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events: At time of intervention, an average of 1 hour Survival: Up to 5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Diagnostic (PET-CT and PET-MRI)</title>
          <description>Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.&#xD;
positron emission tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
computed tomography: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
magnetic resonance imaging: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI&#xD;
fludeoxyglucose F 18: Undergo fludeoxyglucose F 18 PET-CT and PET-MRI</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Raj Paspulati</name_or_title>
      <organization>University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center</organization>
      <phone>1-800-641-2422</phone>
      <email>Raj.Paspulati@UHhospitals.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

